Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Joyce Koh

Gastroenterology Bend, OR Medical Doctor

NPI 1144480484 CMS profile 6551

1342 Ne Medical Center Dr Ste 100, Bend, OR 97701

Open in the dashboard

General payments

$4,048

230 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Joyce Koh of Bend, OR is reported in the CMS Open Payments database as having received $4,048 across 230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $15 1
2023 General $164 4
2022 General $330 17
2021 General $1,444 91
2020 General $712 43
2019 General $1,383 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joyce Koh
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Joyce Koh were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Joyce Koh Gastroenterology median Middle half National median
2019 $1,383 $417 $126–$1,100 $163
2020 $712 $224 $74–$624 $114
2021 $1,444 $352 $106–$1,054 $132
2022 $330 $448 $129–$1,270 $149
2023 $164 $533 $150–$1,390 $160
2024 $15 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $981 76 payments
  2. AbbVie, Inc. $819 39 payments
  3. Gilead Sciences, Inc. $574 26 payments
  4. Intercept Pharmaceuticals, Inc. $328 11 payments
  5. Janssen Biotech, Inc. $324 16 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $190 12 payments
  7. Celgene Corporation $184 17 payments
  8. Nestle HealthCare Nutrition Inc. $128 6 payments
  9. Ironwood Pharmaceuticals, Inc $105 7 payments
  10. Cumberland Pharmaceuticals, Inc. $92 5 payments
  11. Other $324 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,756 208 payments
  2. Education $257 20 payments
  3. Consulting Fee $34 2 payments
Products named General payments · program years 2019–2024
  1. XIFAXAN $1,299 88 payments
  2. HUMIRA $433 21 payments
  3. STELARA $307 15 payments
  4. TRULANCE Gastroenterology $277 19 payments
  5. OCALIVA $267 7 payments
  6. TRULANCE Gastroenterology $214 18 payments
  7. ZEPOSIA $184 17 payments
  8. LINZESS $182 9 payments
  9. MAVYRET $169 7 payments
  10. Vemlidy $145 3 payments
  11. Other $1,425 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

118

Median for Gastroenterology: 569

Drug cost

$7,328

Median for Gastroenterology: $104,976

Branded share of claims

0%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucralfate Generic 14 $4,928
Omeprazole Generic 48 $879
Esomeprazole Magnesium Generic 30 $878
Pantoprazole Sodium Generic 26 $644

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$27,342

Medicare's payments for the services billed

Medicare patients

145

Average age 71

Services billed

209

86 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 39%
Depression 24%
Diabetes 20%
Cancer 19%
Chronic kidney disease 18%
Ischemic heart disease 15%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $7
$7 — —
PLENVU
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record